Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.69 |
| ▸ | TSHR | P16473 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.69 |
| ▸ | MTOR | P42345 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metiprenaline SCHEMBL3217916 | 1.00 | SLC22A3 (1.00) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metiprenaline SCHEMBL2109418 | 1.00 | SLC22A3 (1.00) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metiprenaline SCHEMBL3207430 | 0.98 | SLC22A3 (0.97) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metiprenaline SCHEMBL3220256 | 0.98 | SLC22A3 (0.97) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metiprenaline SCHEMBL5319662 | 0.97 | SLC22A3 (0.94) | SLC22A3MAPTADRB2TSHRKDM4E | |
| SCHEMBL20852599 | 0.88 | SLC22A3 (0.78) | SLC22A3MAPTADRB2TSHRKDM4E | |
| SCHEMBL4882170 | 0.87 | SLC22A3 (0.77) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metanephrine SCHEMBL30512034 | 0.84 | SLC22A3 (0.73) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metanephrine SCHEMBL29569242 | 0.84 | SLC22A3 (0.73) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metanephrine SCHEMBL136702 | 0.84 | SLC22A3 (0.73) | SLC22A3MAPTADRB2TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023028350-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| EP-2117524-B1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NAT RES COUNCIL CANADA (CA) | 2019-08-14 | — | — | EP | disclosed |
| US-20170027889-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170027888-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-9351947-B2 | Use of catecholamines and related compounds as anti-angiogenic agents | NATIONAL RESEARCH COUNCIL OF CANADA | 2016-05-31 | — | — | US | disclosed |
| US-20100069401-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027888-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | ADRB3, ADRB1, ADRA1D | SLC22A3 3816/4885MAPT 2116/4885ADRB2 4/4885 |
| US-20170027889-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | SLC6A2, VEGFA, COMT | SLC22A3 254/4885MAPT 2703/4885ADRB2 7/4885 |
| US-20100069401-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | ADRB2, ADRB1, SLC6A2 | SLC22A3 274/4885MAPT 2957/4885ADRB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.